{
  "docId": "019de074-559c-76fa-9457-a7d91e9a06c5",
  "docSlug": "15199f0b497c4ef204a0760da27401b3",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 54 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 28,
  "pageCount": 54,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a testimonial quote from a Bayer executive.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-559c-76fa-9457-a7d91e9a06c5/28",
  "deckHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5",
  "deckJsonHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5.json",
  "deckAnchorHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.16,
        "y": 0.517
      },
      "kind": "callout",
      "text": "Cooperative Research and Development Agreement (CRADA) for the Pivotal Phase 3 Study",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf5a2cd4-9e63-4a4b-b862-21b3955b52bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.14,
        "x": 0.07,
        "y": 0.517
      },
      "kind": "image",
      "text": "NIH",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44dfd6dd-df45-4dd5-b8e1-0bcf642a9bd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.51,
        "x": 0.42,
        "y": 0.29
      },
      "kind": "list",
      "text": "The pivotal Phase 3 study will be supported by the NICHD’s Contraceptive Development Program... Daré will be responsible for providing clinical supplies... Under the CRADA, Daré also agreed to contribute $5.5 million toward the total estimated cost...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5487ec9e-df62-43d5-90de-9ac44c7ad07a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.37,
        "x": 0.07,
        "y": 0.29
      },
      "kind": "paragraph",
      "text": "July 2021 – Daré announced that funding and clinical operations support for the Phase 3 will be provided by the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Under the CRADA",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb61977c-fc53-4979-9ac5-567399176cb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.93,
        "x": 0.07,
        "y": 0.71
      },
      "kind": "quote",
      "text": "“This collaboration between Daré and NICHD marks an important milestone in Women’s Healthcare Innovation... We’re For Her to provide women with education and access to contraceptive options,” said John Berrios, Bayer’s Head of Women’s Healthcare.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7098bb61-db2b-438c-b960-5cd6e61a5698",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.6,
        "x": 0.07,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. https://ir.darebioscience.com/news-releases/news-release-details/dare-announces-collaborative-research-agreement-crada-pivotal",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b78d419-9d52-4b9c-b700-5c56aa67b795",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.68,
        "x": 0.16,
        "y": 0.16
      },
      "kind": "title",
      "text": "Ovaprene® - Collaborative Research Agreement with NIH¹",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30e5354d-2c37-40e4-9ee7-7db8ec3037c5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 54,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "2cf418f8-2568-4e9a-bf9d-f55bdd0bfb9e",
      "evidence": "The deck implies that inaction in women's health has significant consequences",
      "position": 0,
      "objective": "What is the cost of inaction in women's health?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}